You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 878 BET inhibition sensitizes immunologically-cold Rb-deficient prostate cancer to immune checkpoint blockade via DNA damage-induced STING/NF-κB/type I IFN signaling

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
878 BET inhibition sensitizes immunologically-cold Rb-deficient prostate cancer to immune checkpoint blockade via DNA damage-induced STING/NF-κB/type I IFN signaling
Free

Authors

Citation

Chaudagar K, Li M, Hong C, et al
878 BET inhibition sensitizes immunologically-cold Rb-deficient prostate cancer to immune checkpoint blockade via DNA damage-induced STING/NF-κB/type I IFN signaling
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0878

Publication history

  • First published November 7, 2022.
Online issue publication 
April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.